You must be 21 years or older to access this website. All products are for research use only.
Are you 21 years of age or older?
By entering, you confirm that you are at least 21 years old and agree to our terms of service.
GHK-Cu · Published March 8, 2026 · Updated May 18, 2026 · 7 min read
GHK-Cu is a copper-binding tripeptide studied in preclinical research for skin regeneration, including keratinocyte interactions, wound healing acceleration, and collagen production. Studies examine extracellular matrix repair, dermal fibroblast activity, and tissue regeneration biology across cellular and rodent skin research models. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
Products sold by Midwest Peptide are intended for laboratory and research use only. Not for human consumption. These products are not drugs, supplements, or intended to diagnose, treat, cure, or prevent any disease.
GHK-Cu is a copper-bound tripeptide composed of glycine, histidine, and lysine complexed with a Cu(II) ion. It occurs naturally in human plasma and is studied in preclinical models for collagen synthesis, dermal fibroblast activity, and tissue regeneration.
Mechanisms include keratinocyte and fibroblast proliferation, copper-mediated lysyl oxidase activity for collagen crosslinking, ECM remodeling through balanced MMP/TIMP expression, and angiogenic support via VEGF and other growth factor signaling.
Methods include histological re-epithelialization scoring, wound closure rate measurements, transepidermal water loss (TEWL) assessment, and molecular markers of differentiation including involucrin, filaggrin, and keratin expression.
No. GHK-Cu is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.
Key terms used in this article.
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
GHK-Cu is a naturally occurring copper-binding peptide that has become a subject of interest in scientific research due to its reported effects on tissue repair and skin regeneration. Laboratory studies have examined how it may influence cellular pathways, collagen production, and wound healing in preclinical models, providing insights for researchers exploring tissue recovery mechanisms.
In preclinical studies, GHK-Cu has been shown to interact with cells involved in tissue repair, including fibroblasts and keratinocytes. Researchers are exploring its potential to modulate gene expression related to collagen synthesis, extracellular matrix (ECM) remodeling, and anti-inflammatory pathways.
Scientific investigations focus on how GHK-Cu influences cellular signaling. Researchers specifically study its effects on:
Most GHK-Cu studies are conducted in animal or cell culture models. These experiments simulate skin injury or connective tissue damage to explore mechanisms of repair and tissue remodeling. Laboratory findings provide valuable data for understanding how peptides may influence recovery at the molecular level.
High-fidelity research requires high-purity compounds. Midwest Peptide ensures that every batch of GHK-Cu is verified through independent third-party HPLC and Mass Spec analysis to maintain 99%+ purity. We provide the transparency and documentation, including a Certificate of Analysis (COA) with every order, necessary to ensure that your laboratory results are accurate and reproducible.
The functional characterization of GHK-Cu in connective-tissue biology traces back to the 1988 FEBS Letters report by Maquart and colleagues, who demonstrated that the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulated collagen synthesis in cultured human dermal fibroblasts at concentrations between 10^-12 M and 10^-9 M, with peak activity at 1 nM and no parallel increase in cell number. That dissociation between proliferative effects and matrix output is one reason GHK-Cu remains a reference ligand for studying selective extracellular-matrix remodeling in laboratory models. The same series of experiments reported parallel stimulation of dermatan sulfate, chondroitin sulfate, and the small leucine-rich proteoglycan decorin, suggesting coordinated up-regulation of the broader proteoglycan compartment rather than a single fiber-forming pathway. The Wiley-hosted version of the paper is available on the FEBS Letters archive at onlinelibrary.wiley.com, and the same record is mirrored through ScienceDirect.
Subsequent work shifted from bulk biochemistry to transcriptomics. Microarray screens have reported that GHK at sub-micromolar concentrations modulates expression of a striking fraction of the human genome, with up-regulation skewed toward DNA-repair, antioxidant-response, and ubiquitin-proteasome programs and down-regulation skewed toward pro-fibrotic and pro-inflammatory clusters. For researchers building in vitro screens for tissue-remodeling compounds, this transcriptional signature is a useful positive control: GHK-Cu at 1 to 10 nM should reproducibly shift fibroblast and keratinocyte expression toward a less-senescent profile within 24 to 72 hours of exposure. Cross-references within recent reviews on copper-peptide signaling are aggregated at the ScienceDirect copper-peptide topic page.
Reconstitution variables materially affect data reproducibility. GHK-Cu has a molecular weight of 402.9 g/mol for the copper-bound complex (GHK alone is 340.4 g/mol); a 50 mg vial dissolved in 2 mL of bacteriostatic water yields a 25 mg/mL stock, with 1 to 10 nM working dilutions appropriate for fibroblast cultures based on the dose-response published by Maquart and later groups. The Cu2+ binding affinity is high (log K near 16.4 at physiological pH), so divalent cations in the buffer or chelators such as EDTA can shift the equilibrium and bias collagen-synthesis endpoints. Sterile filtration through 0.22 micron PES membranes preserves activity; freeze-thaw cycles beyond three should be avoided in stability-sensitive assays.
For wound-closure screens in monolayer scratch assays, common endpoints include time to 50 percent gap closure, immunostaining for Type I procollagen, and qPCR for MMP-1, MMP-2, TIMP-1, and TIMP-2. GHK-Cu typically shortens 50 percent closure times in primary dermal fibroblast monolayers without altering cell viability as measured by MTT or resazurin assays. In organotypic skin-equivalent models, endpoints expand to include basement-membrane integrity (laminin-5 and collagen IV staining), basal keratinocyte proliferation (Ki-67 index), and dermal thickness on histology. Investigators comparing batches should always confirm copper saturation by UV-visible spectroscopy at 525 nm, where the GHK-Cu complex shows a characteristic d-d absorbance band that is absent from the apo-peptide.
Researchers extending this work into broader wound-healing reviews can cross-reference the Nature subject hub for wound healing for adjacent literature on angiogenic signaling, keratinocyte migration, and matrix turnover, all of which intersect with GHK-Cu mechanisms. For methodology comparisons with related copper-loaded peptides and tripeptide derivatives, see our internal write-ups on GHK-Cu anti-fibrotic studies and the GHK-Cu photoaging and senescence research recap. Sourcing notes for laboratory inventory are collected in the GHK-Cu sourcing guide.
A practical caveat for new investigators: many published GHK studies use the apo-peptide rather than the copper-saturated complex, and the two forms differ in their transcriptional output. Apo-GHK has intrinsic activity through MMP modulation and growth-factor potentiation, but only the copper-loaded form reliably engages the antioxidant and DNA-repair clusters that drive the most cited fibroblast phenotypes. When designing a comparative screen, hold copper stoichiometry constant across treatment arms and report it explicitly in the methods. This single methodological choice resolves a large share of the variance reported across published replication attempts of the 1988 Maquart dataset and aligns downstream qPCR and immunostaining results with the historical literature.
Investigators should also be deliberate about culture media composition. Standard DMEM and DMEM/F12 formulations contain trace copper and ascorbate that interact with GHK-Cu in ways that can mask treatment effects at the low nanomolar range. For dose-response studies below 10 nM, switch to a defined serum-free medium or pre-dialyze the serum component against Chelex resin. Pair every GHK-Cu arm with an apo-GHK arm and a copper-only arm to deconvolute the metal contribution from the peptide-driven transcriptional shift. These three controls turn a single observation into a mechanistically interpretable experiment and bring GHK-Cu data in line with the standards used in the Frontiers in Pharmacology cosmetic-peptide review series.
Primary literature and topic hubs from peer-reviewed publishers covering this area of research:
Explore more peer-reviewed research and laboratory guides from our science team:
All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.
Browse our full catalog of research-grade peptides. Every product is third-party tested with a COA included.
Browse ProductsMidwest Peptide supplies research-grade GHK-Cu with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.
The cheapest tirzepatide (GLP-2 TZ) for research is rarely the best value. Here is how to balance price against the analytical specifications that determine research utility.
May 5, 2026
